Britannia Life Sciences Inc.
BLSIF
$0.0666
-$0.0114-14.62%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 122.70K | -- | 1.24M | 1.43M | 113.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.70K | -- | 1.24M | 1.43M | 113.80K |
| Cost of Revenue | 102.30K | -- | 518.20K | 468.40K | 41.50K |
| Gross Profit | 20.50K | -- | 723.40K | 965.40K | 72.30K |
| SG&A Expenses | 271.10K | -- | 845.60K | 548.60K | 305.30K |
| Depreciation & Amortization | 11.30K | -- | -- | -- | 10.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 384.60K | -- | 1.36M | 1.02M | 357.50K |
| Operating Income | -261.90K | -- | -122.20K | 416.80K | -243.70K |
| Income Before Tax | -499.40K | -- | -24.10K | -685.50K | -666.30K |
| Income Tax Expenses | -- | -- | 43.60K | 108.00K | -- |
| Earnings from Continuing Operations | -499.40K | -- | -67.70K | -793.50K | -666.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 176.10K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -30.10K | -82.30K | -49.30K |
| Net Income | -499.40K | -- | -97.80K | -875.80K | -539.40K |
| EBIT | -261.90K | -- | -122.20K | 416.80K | -243.70K |
| EBITDA | -250.60K | -- | -102.90K | 435.10K | -233.00K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | -0.01 | -- | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | -0.01 | -- | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Average Diluted Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |